Privigen 10% vial 100ML
Ended Awarded Last action
- Contract number
- SPE2DR26FHKS0
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $20,945
Award facts
- Contract value 100% obligated
- $20,944.80 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency has awarded a $20,944.80 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Privigen 10% Vial 100ML, a critical immunoglobulin product for Department of Defense medical operations. The award, issued on December 1, 2025, with an ultimate completion date of December 22, 2025, carries no set-aside designation, reflecting the contractor's competitive capability in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a comprehensive $30.3 billion acquisition strategy designed to establish multiple regional prime vendor contractors supporting recurring pharmaceutical supply needs for military healthcare facilities worldwide.
DMS Pharmaceutical Group's PPV-G GEN V contract, designated SPE2DR and awarded on November 13, 2025, carries a ceiling value of $499,999,999 with a completion date of December 31, 2036, structured as a 30-month base period plus three 30-month option periods. The contractor's established performance on numerous delivery orders across a diverse pharmaceutical portfolio—including oncology treatments, biologics, vaccines, specialty medications, and medical consumables—demonstrates its capability to fulfill the specialized requirements of the Department of Defense military medical system. The delivery order represents routine replenishment of critical immunological products essential to military healthcare operations, consistent with DMS Pharmaceutical Group's role as a primary pharmaceutical supplier within the federal military medical supply chain.
Quick answers
Who was awarded contract SPE2DR26FHKS0?
SPE2DR26FHKS0 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 1, 2025.
How much is contract SPE2DR26FHKS0 worth?
The government has obligated $20,945 on SPE2DR26FHKS0.
Is contract SPE2DR26FHKS0 an order under another contract?
Yes. SPE2DR26FHKS0 is a delivery order under SPE2DR25D9222, an indefinite delivery contract.
Was contract SPE2DR26FHKS0 competed?
The extent of competition for SPE2DR26FHKS0 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award